- Home
- CHY vs OPK Comparison
CHY vs OPK Comparison
Compare CHY & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- OPK
- Stock Information
- Founded
- CHY 2003
- OPK 2007
- Country
- CHY United States
- OPK United States
- Employees
- CHY N/A
- OPK N/A
- Industry
- CHY Investment Managers
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- CHY Finance
- OPK Health Care
- Exchange
- CHY Nasdaq
- OPK Nasdaq
- Market Cap
- CHY 913.3M
- OPK 1.0B
- IPO Year
- CHY N/A
- OPK 1995
- Fundamental
- Price
- CHY $12.01
- OPK $1.49
- Analyst Decision
- CHY
- OPK Strong Buy
- Analyst Count
- CHY 0
- OPK 3
- Target Price
- CHY N/A
- OPK $2.75
- AVG Volume (30 Days)
- CHY 128.3K
- OPK 3.5M
- Earning Date
- CHY 01-01-0001
- OPK 11-04-2024
- Dividend Yield
- CHY 10.11%
- OPK N/A
- EPS Growth
- CHY N/A
- OPK N/A
- EPS
- CHY N/A
- OPK N/A
- Revenue
- CHY N/A
- OPK $716,372,000.00
- Revenue This Year
- CHY N/A
- OPK N/A
- Revenue Next Year
- CHY N/A
- OPK $1.36
- P/E Ratio
- CHY N/A
- OPK N/A
- Revenue Growth
- CHY N/A
- OPK N/A
- 52 Week Low
- CHY $9.97
- OPK $0.85
- 52 Week High
- CHY $12.16
- OPK $1.75
- Technical
- Relative Strength Index (RSI)
- CHY 60.95
- OPK 44.15
- Support Level
- CHY $11.71
- OPK $1.46
- Resistance Level
- CHY $11.99
- OPK $1.58
- Average True Range (ATR)
- CHY 0.17
- OPK 0.08
- MACD
- CHY -0.00
- OPK -0.01
- Stochastic Oscillator
- CHY 71.43
- OPK 16.13
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.